AC whoever wrote this article needs to research their subject matter to a higher level.
Quote from article.
"The second asset (INV-104) is a “proposed” inhalable form of leukotriene receptor antagonist (LTRA), zafirlukast. This is an asthma prevention drug that is marketed by AstraZeneca as Accolate, but is now off-patent. I’m not going to spend too much time talking about this asset because it is fundamentally stupid and irrelevant."
This drug was developed under the leadership of our CMO Dr. Mitchell Glass.
"Dr Mitchell Glass, Invion’s Executive Vice President of R&D and Chief Medical Officer, led the development and submission of Accolate for Zeneca (now AstraZeneca) to its FDA approval letter in 1998, and is a substantial shareholder of Accolade Pharma LLC."
"The oral formulation of zafirlukast, currently marketed as a generic drug as well as by AstraZeneca as Accolate, has recently become available in the public domain due to the expiry of its original patents. Accolade Pharma LLC has created a patent strategy and strategic opportunities to develop non-oral formulations of the drug, aimed at reducing side effects and increasing effectiveness"
AstraZeneca tried to formulate an inhaled version but failed.
- Forums
- ASX - By Stock
- IVX
- INVO2 can Repair Damaged LUNGS
INVO2 can Repair Damaged LUNGS, page-22
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IVX (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $19.81M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.3¢ | $29.55K | 9.851M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 4451823 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 4794077 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 3643334 | 0.003 |
11 | 14533666 | 0.002 |
14 | 18233318 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 4794077 | 9 |
0.005 | 9073292 | 24 |
0.006 | 3799372 | 12 |
0.007 | 3518975 | 7 |
0.008 | 4405000 | 5 |
Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
Featured News
DVP
Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place
GML
Gateway Mining sells WA Eastern Montague gold project to Brightstar for $14M – half of that in shares
IVX (ASX) Chart |